Agilent A

Agilent Technologies reported strong revenue growth of $1.86 billion for the latest quarter, a 9.4% increase from the previous year, surpassing analysts' expectations. However, the company's stock fell by 10.6% amid concerns over a stagnating sales trend and declining organic revenue performance. Despite positive developments such as the acquisition of Biocare Medical and partnerships with AWS and NVIDIA to enhance genomics capabilities, investor confidence has waned due to a drop in free cash flow margins and a flat sales growth outlook.